Collectively, these findings uncover a previously unrecognized role of CDC42 in AKI pathogenesis and highlight CDC42 inhibition as a promising therapeutic strategy for mitigating mitochondrial damage and improving renal outcomes. This evidence concerns the gene CDC42 and acute kidney injury.